Nevro Corp. NVRO recently received CE Mark Certification in Europe for its HFX iQ spinal cord stimulation (SCS) system. The company can now market HFX iQ in all countries that recognize this ...
Nevro NVRO recently announced the FDA clearance and limited market release of HFX iQ with HFX AdaptivAI, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation ...
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...
Shares of Nevro Corp. NVRO gained 5% on Oct 13, following the announcement of the FDA approval for its spinal cord stimulation (SCS) system — Senza HFX iQ — for the treatment of chronic pain. The new ...
Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., March 7, 2023 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback